Research & Development World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • COVID-19
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
      • Software
    • Semiconductors
  • 2021 R&D 100 Award Winners
    • R&D 100 Awards
    • 2020 Winners
    • Winner Archive
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • Global Funding Forecast
  • Webinars

Amyloid Mass Spectrometry supports Alzheimer’s drug discovery and development

By Heather Hall | July 8, 2022

Shimadzu Scientific Instruments announces the successful commercialization of a new Amyloid Mass Spectrometry (MS) Service for the early screening of amyloid-positive individuals. This simple, research-use-only blood-based analysis method enables reliable characterization of amyloid pathology in the brain with an easy-to-acquire blood sample to assist in the evaluation and development of new pharmaceutical treatments for Alzheimer’s disease.

Although the screening analysis is for research use only and cannot diagnose Alzheimer’s disease, it is ideal for opening the door to new advancements in research, identifying suitable candidates for clinical trials and helping pharmaceutical companies in their testing of candidate drugs.

Unlike conventional positron emission tomography (PET) imaging and cerebrospinal fluid (CSF) testing methods, Shimadzu’s blood amyloid-beta analysis method is minimally invasive and suitable for large-scale deployment. This new approach to blood analysis is capable of being used for predicting abnormal amyloid-beta concentration, which can be a marker for amyloid pathology in the brain. New blood-based biomarkers were discovered in 2014 by Shimadzu Corporation and the Japanese National Center for Geriatrics and Gerontology (NCGG).

The blood analysis works using a combination of immunoprecipitation and MALDI-TOF mass spectrometry (IP-MS). This technique was first established by a team of scientists including Shimadzu’s Koichi Tanaka, who was awarded the Nobel Prize in chemistry in 2002 for developing a method for mass spectrometric analysis of biological macromolecules.

Experts from Shimadzu will present information about the Amyloid Mass Spectrometry (MS) Service at booth 206 at the Alzheimer’s Association International Conference from July 31–August 4, 2022, in San Diego.

For more information about Shimadzu’s Amyloid MS Service, click here.

Find more scientific background about Shimadzu’s blood amyloid-beta analysis here: A. Nakamura, N. Kaneko et al., “High performance plasma amyloid-β biomarkers for Alzheimer’s disease” doi: 10.1038/nature 25456.

 

Comments

  1. Victor says

    July 9, 2022 at 8:18 pm

    I recently lost a friend to complications of amyloid accumulation in the brain and heart, maybe he could have been diagnosed early and have a chance of treatment and survival.

    Reply

Tell Us What You Think! Cancel reply

Related Articles Read More >

Shimadzu’s new spectrometer provides high-speed, high-resolution detection
Torrey Pines Scientific’s EchoTherm HPLC Column Oven with temperature control
Raman Spectroscopy: The new standard in compositional analysis of polymers
What are pipette controllers?
2021 R&D Global Funding Forecast

Need R&D World news in a minute?

We Deliver!
R&D World Enewsletters get you caught up on all the mission critical news you need in research and development. Sign up today.
Enews Signup

R&D World Digital Issues

February 2020 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R& magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • 2022 Global Funding Forecast

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • COVID-19
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
      • Software
    • Semiconductors
  • 2021 R&D 100 Award Winners
    • R&D 100 Awards
    • 2020 Winners
    • Winner Archive
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • Global Funding Forecast
  • Webinars